GLP-1 and health: Beyond weight loss in the Ozempic era
This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss drugs, Wegovy and Zepbound. The move could significantly expand access to these treatments for people with diabetes and obesity.
Source: Medical Xpress